Compare Freshworks Inc (FRSH) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Novavax Inc — how do they compare? Freshworks Inc trades at $10.75 (market cap $2.93B), while Novavax Inc trades at $8.27 (market cap $1.39B). The key difference: Freshworks Inc is far larger — about 2.1× Novavax Inc's market cap. Which is the better fit depends on your goals.
| FRSH | NVAX | |
|---|---|---|
Market Cap | $2.93B | $1.39B |
Sector | Technology | Health |
52-Week High | $14.77 | $11.19 |
52-Week Low | $6.88 | $6.22 |
Enterprise Value | $2.19B | $890.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $10.47, down 3.32% on the day, with a bullish technical signal from moving averages. The company shows a strong fundamental turnaround, achieving profitability in 2025 with a net income margin of 20.69% and robust revenue growth from $498M in 2022 to $839M in 2025. Recent news highlights a strategic pivot to its employee experience (EX) business and new AI product launches, with the Q2 2026 earnings report scheduled for August 4, 2026.
The outlook is positive, supported by a profitable growth trajectory, a 50% analyst buy rating, and a significant valuation discount to software peers. Key risks include execution of the EX pivot, competitive pressures in SaaS, and the need to sustain high gross margins. The stock offers opportunity as a value play with accelerating fundamentals, but faces typical growth stock volatility.
Novavax (NVAX) trades at $8.42, down 5.5% on the day, reflecting a bearish technical trend. Despite a low P/E of 3.14 and recent earnings beats, the company reported a net loss margin of -14.73% for 2026 and negative cash flows. Analyst consensus is a 'Buy' with a $14.00 price target, but technical indicators signal selling pressure. Recent news highlights stock volatility and shareholder dissent at the AGM.
The outlook is mixed: strong valuation ratios and earnings beats offer upside potential, but persistent negative cash flow, high debt, and competitive pressures pose significant risks. Investor sentiment is cautious amid bearish technical signals and uncertain revenue sustainability beyond 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
